Patient Experience Survey Updates

Pediatric Patient Summary, May 10, 2020

Age
<55612.6%
5-913530.5%
10-1414833.4%
15-179721.9%
Gender
Male15835.7%
Female28163.4%
Non-binary/Prefer not to answer40.9%
Country
USA20146.1%
Italy4710.8%
UK276.2%
Chile184.1%
Canada173.9%
Other12628.9%
US State
Texas2110.6%
California157.5%
Virginia 105.0%
Georgia94.5%
Massachusetts94.5
Other13567.8%
Race/ethnicity
White35273.6%
Latin American 5611.7%
Black173.6%
Other255.2%
Rheumatic disease
JIA (not systemic)13525.1%
Systemic JIA11922.1%
Autoinflammatory disease6411.9%
Lupus468.5%
Other17532.5%
Medications
Methotrexate14319.2%
Prednisone11315.2%
TNF-inhibitors9412.6%
IL-1 inhibitors7810.5%
Hydroxychloroquine618.2%
Other689.1%
COVID-19 diagnosis
Yes51.21%
COVID-19 severity
No limitations in activities, not hospitalized240%
Some limitations in activities, not hospitalized360%
Pediatric patients (n=443) from the COVID-19 Global Rheumatology Alliance Patient Experience Survey

All Patients Summary, April 16, 2020

 
 
9541 respondents
 
95% adults, 5% children (parents responded on their child’s behalf)
 
25% with rheumatoid arthritis
20% systemic lupus erythematosus
9% Sjogren’s syndrome
7% ankylosing spondylitis
 
465 patients reported COVID-19 diagnoses (about 5% of respondents)
 
159 dx themselves based on symptoms
122 dx by a physician based on symptoms
55 dx by a physician based on laboratory tests
87 other (e.g. exposure to a case, presence of symptoms but negative testing, etc.)
 
2694 of the entire cohort was taking HCQ at the time of the survey (28% of cohort)
 
2505 did NOT have COVID-19 (93%)
189 DID have COVID-19 (7%)